Pharmacyclics LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- 607
- Market Cap
- -
- Website
- http://www.pharmacyclics.com
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Renal CellUrogenital NeoplasmsUrologic NeoplasmsKidney Neoplasms
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2007-03-05
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 43
- Registration Number
- NCT00134186
- Locations
- 🇺🇸
Methodist Hospital, Houston, Texas, United States
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
Phase 2
Completed
- Conditions
- AdenocarcinomaNon-Small-Cell Lung CarcinomaLung Neoplasms
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2008-08-20
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 108
- Registration Number
- NCT00129844
Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
Phase 2
Terminated
- Conditions
- Neoplasm MetastasisBrain Neoplasms
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 45
- Registration Number
- NCT00121420
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Phase 1
Completed
- Conditions
- Breast NeoplasmsOvarian NeoplasmsProstatic NeoplasmsLung NeoplasmsGastrointestinal Neoplasms
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 25
- Registration Number
- NCT00120939
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Non-Small-Cell Lung CarcinomaCarcinoma, Bronchogenic
- First Posted Date
- 2005-01-31
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 36
- Registration Number
- NCT00102505
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2
Terminated
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- First Posted Date
- 2005-01-05
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 27
- Registration Number
- NCT00100711
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
🇺🇸The Mayo Clinic, Rochester, Minnesota, United States
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- First Posted Date
- 2004-11-17
- Last Posted Date
- 2006-06-08
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 25
- Registration Number
- NCT00096837
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- LymphomaNon-Hodgkin's Lymphoma
- First Posted Date
- 2004-06-23
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 35
- Registration Number
- NCT00086034
Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases
Phase 3
Completed
- Conditions
- Metastatic Cancer
- Interventions
- Radiation: WBRTDrug: MGd
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 430
- Registration Number
- NCT00003563
- Locations
- 🇺🇸
Beckman Research Institute, City of Hope, Los Angeles, California, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Vanderbilt Cancer Center, Nashville, Tennessee, United States
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Ovarian NeoplasmsProstatic NeoplasmsLung NeoplasmsBreast Neoplasms
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 20
- Registration Number
- NCT00080041
- Locations
- 🇺🇸
University of Rochester Cancer Center, Rochester, New York, United States
© Copyright 2025. All Rights Reserved by MedPath